Astellas Pharma revenue and financials
¥2,255.50Change from previous close: +0.53%Absolute change: +¥12.00
In the fiscal year ended March 2026, Astellas Pharma reported revenue of ¥2.14T (+11.87% year over year). Net income was ¥291.54B, a net margin of 13.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.87%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +474.49%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 13.6%
- FY to Mar 2025: 2.7%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Operating cash flow | 560,188 | 194,512 | 172,475 | 327,767 | — |
| Depreciation and amortization | 194,594 | 199,132 | 157,840 | 105,738 | — |
| Capital expenditure | -84,645 | -57,330 | -82,497 | -88,541 | — |
| Investing cash flow | -66,722 | -89,419 | -845,802 | -84,500 | — |
| Financing cash flow | -404,779 | -261,367 | 614,060 | -195,623 | — |
| Dividends paid | -136,099 | -128,993 | -116,653 | -100,355 | — |
| Share repurchases | -730 | -6,960 | -10,735 | -60,556 | — |
| Debt issued | 0.0 | 200,000 | 472,275 | 50,000 | — |
| Debt repaid | -81,793 | -52,073 | -25,379 | -50,000 | — |
| Effect of exchange rates | 4,547 | 8,960 | 18,113 | 13,210 | — |
| Net change in cash | 88,687 | -156,274 | -59,267 | 47,644 | — |
| Free cash flow | 475,543 | 137,182 | 89,978 | 239,226 | — |